Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
- February -
March
-
April
-
May
-
June
-
July
-
August
- September -
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
-
2024
- 2025 -
2026
February 2025 - 43 products
IP
CI
Teriflunomid Devatis 14 mg
28
365.21
414.80
10 %
Coated tablets: Teriflunomidum 14 mg
Devatis AG
B / SL / SG
FB
G
IP
CI
Teriflunomid Devatis 14 mg QOD
28
365.21
414.80
10 %
Coated tablets: Teriflunomidum 14 mg
Devatis AG
B / SL / SG
FB
G
IP
CI
Teriflunomid Devatis 14 mg
84
1095.76
1211.65
10 %
Coated tablets: Teriflunomidum 14 mg
Devatis AG
B / SL / SG
FB
G
L
IP
CI
Tofacitinib Sandoz 5 mg
56
372.99
422.05
10 %
Coated tablets: Tofacitinibum 5 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CI
Tofacitinib Sandoz 10 mg
56
627.64
699.00
10 %
Coated tablets: Tofacitinibum 10 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
CI
WAINZUA
30703.11
31809.20
10 %
AstraZeneca AG
B / SL
FB
G
L
IP
Briumvi 25 mg/ml
2134.91
2338.25
10 %
Concentrate for infusion: Ublituximabum 150mg / 6ml
Neuraxpharm
Switzerland AG
A / SL
FB
G
L
IP
Briumvi 25 mg/ml
3
6404.74
6879.05
10 %
Concentrate for infusion: Ublituximabum 150mg / 6ml
Neuraxpharm
Switzerland AG
A / SL
FB
G
L
IP
CI
Lazcluze 80 mg
56
5536.84
5988.60
10 %
Coated tablets: Lazertinibum 80 mg
Janssen-Cilag AG
A / SL
FB
G
L
IP
CI
Lazcluze 240 mg
28
6292.08
6763.45
10 %
Coated tablets: Lazertinibum 240 mg
Janssen-Cilag AG
A / SL
FB
G
L
IP
CI
Andembry 200 mg
15448.98
16158.45
10 %
Injektionslösung im Fertigpen: Garadacimabum 200mg / 1.2ml
CSL Behring AG
B / SL
FB
G
L
IP
CI
Nemluvio 30 mg
30 mg
1905.50
2088.75
10 %
Pulver und Lösungsmittel für Injektionslösung im Fertigpen: Nemolizumabum 30 mg
Galderma SA
B / SL
FB
G
IP
CI
Rystiggo 280 mg/ 2ml
k.A.
Injection solution: Rozanolixizumabum 140 mg/ml
UCB-Pharma SA
A
FB
G
IP
CI
Vyvgart 1000 mg/ 5.6 ml
k.A.
Injection solution: Efgartigimodum Alfa 1000mg / 5.6ml
argenx Switzerland SA
A
FB
G
IP
CI
Litfulo 50 mg
30
k.A.
Capsules: Ritlecitinibum 50 mg
Pfizer AG
B
FB
G
IP
CI
Fintepla 2.2 mg/ml
120 ml
k.A.
Solution (oral): Fenfluraminum 2.2 mg/ml
UCB-Pharma SA
A
FB
G
IP
CI
Fintepla 2.2 mg/ml
360 ml
k.A.
Solution (oral): Fenfluraminum 2.2 mg/ml
UCB-Pharma SA
A
FB
G
IP
Tigecyclin Leman 50 mg
10
k.A.
Poudre pour solution à diluer pour perfusion: Tigecyclinum 50 mg
Leman SKL SA
A
FB
G
IP
Vyloy 100 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 100 mg
Astellas Pharma AG
A
FB
G
IP
Vyloy 100 mg
3
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 100 mg
Astellas Pharma AG
A
FB
G
IP
CI
MyLoop
k.A.
anneau vaginal: 2 Active Agents
Labatec Pharma SA
B
FB
G
IP
CI
MyLoop
3
k.A.
anneau vaginal: 2 Active Agents
Labatec Pharma SA
B
FB
G
IP
VISICLOR 30 mg/g
0.8 g
k.A.
Sintetica SA
B
FB
G
IP
VISICLOR 30 mg/g
10 x 0.8 g
k.A.
Sintetica SA
B
FB
G
IP
VISICLOR 30 mg/g
20 x 0.8 g
k.A.
Sintetica SA
B
FB
G
IP
VISICLOR 30 mg/g
50 x 0.8 g
k.A.
Sintetica SA
B
FB
G
Piasky 340 mg/ 2 ml
k.A.
Infusion solution: Crovalimabum 340 mg
Roche Pharma
(Schweiz) AG
A
FB
G
IP
CI
Crysalis Leman
30 g
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
IP
CI
Crysalis Leman
60 g
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
IP
CI
Crysalis Leman
2 x 60 g
k.A.
Gel: 2 Active Agents
Leman SKL SA
B
FB
G
IP
CI
Gabapentin-Mepha Teva 100 mg
50
k.A.
Capsules: Gabapentinum 100 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 100 mg
100
k.A.
Capsules: Gabapentinum 100 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 100 mg
200
k.A.
Capsules: Gabapentinum 100 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 300 mg
50
k.A.
Capsules: Gabapentinum 300 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 300 mg
100
k.A.
Capsules: Gabapentinum 300 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 300 mg
200
k.A.
Capsules: Gabapentinum 300 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 400 mg
50
k.A.
Capsules: Gabapentinum 400 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 400 mg
100
k.A.
Capsules: Gabapentinum 400 mg
Mepha Pharma AG
B
FB
G
IP
CI
Gabapentin-Mepha Teva 400 mg
200
k.A.
Capsules: Gabapentinum 400 mg
Mepha Pharma AG
B
FB
G
IP
Vyloy 300 mg
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Zolbetuximabum 300 mg
Astellas Pharma AG
A
FB
G
IP
CI
Nemluvio 30 mg
2 x 30 mg
k.A.
Pulver und Lösungsmittel für Injektionslösung im Fertigpen: Nemolizumabum 30 mg
Galderma SA
B
FB
G
IP
CI
Nortriptyline Rivopharm 10 mg
50
k.A.
compresse rivestite con film: Nortriptylinum 10 mg
Rivopharm SA
B
FB
G
IP
CI
Nortriptyline Rivopharm 25 mg
50
k.A.
compresse rivestite con film: Nortriptylinum 25 mg
Rivopharm SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
